Aytu BioPharma, Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|
| Revenue | $3.7M | $3.2M | $2.6M | $261.8K | $58.9K |
| Cost of Revenue | $2.1M | $1.4M | $957.1K | $88.1K | — |
| Gross Profit | $1.6M | $1.8M | $1.6M | $173.7K | — |
| Gross Margin | 44.0% | 56.0% | 62.6% | 66.3% | — |
| Operating Expenses | |||||
| Research & Development | $167.6K | $959.9K | $6.1M | $3.2M | $3.9M |
| SG&A Expense | $17.7M | $17.4M | $8.5M | $4.0M | $2.3M |
| Operating Income | $-19.7M | $-20.1M | $-21.7M | $-7.6M | $-6.3M |
| Operating Margin | -538.2% | -624.7% | -847.0% | -2,915.5% | -10,770.3% |
| Interest Expense | $749.4K | $2.5M | $5.5M | $115.0K | — |
| Pretax Income | — | — | $-28.2M | $-7.7M | $-6.4M |
| Income Tax Expense | $0 | $0 | $0 | $-23.9K | $-813.7K |
| Net Income | $-10.2M | $-22.5M | $-28.2M | $-7.7M | $-5.6M |
| Net Margin | -278.3% | -698.7% | -1,099.7% | -2,950.3% | -9,466.8% |
| EPS (Basic) | $-7.66 | $-24.15 | $-161.85 | $-5.04 | $-0.40 |
| EPS (Diluted) | $-7.66 | $-24.15 | $-161.85 | $-5.04 | $-0.40 |
| Shares Outstanding (Basic) | 3.6M | 8.0M | 10.1M | 28.5M | 15.8M |
| Shares Outstanding (Diluted) | 3.6M | 8.0M | 10.1M | 28.5M | 15.8M |
| Dividends Per Share | — | — | — | — | — |